Effect of ionic strength on solution stability of PNU-67590A, a micellar prodrug of methylprednisolone. 1997

H Okamoto, and K Mori, and K Ohtsuka, and H Ohuchi, and H Ishii
Pharmacia & Upjohn, Tsukuba Research Laboratories, Ibaraki, Japan. hirokazu.okamoto@am.pnu.com

OBJECTIVE PNU-67590A is a water-soluble micellar prodrug of methylprednisolone (MP). The major products of degradation of PNU-67590A are MP by hydrolysis and methylprednisolone 17-suleptanate (17-E) by 21-->17 acyl migration. The effect of ionic strength on micelle formation and stability of PNU-67590A in aqueous solution was examined. METHODS PNU-67590A solutions at pH 2 and 8 and ionic strength of 0.05, 0.1, 0.2, and 0.4 M were maintained at 25 degrees C in the dark to measure MP and 17-E levels over time. RESULTS The rate of degradation of micellar PNU-67590A at pH 8 was less than that of monomeric PNU-67590A, and vice versa at pH 2. Increase in ionic strength decreased both the critical micelle concentration of PNU-67590A and the degradation of micelle PNU-67590A at both pHs, resulting in improved overall stability of PNU-67590A. CONCLUSIONS Formulation of PNU-67590A in a concentrated solution with high ionic strength will maximize stability and shelf-life.

UI MeSH Term Description Entries
D007477 Ions An atom or group of atoms that have a positive or negative electric charge due to a gain (negative charge) or loss (positive charge) of one or more electrons. Atoms with a positive charge are known as CATIONS; those with a negative charge are ANIONS.
D008775 Methylprednisolone A PREDNISOLONE derivative with similar anti-inflammatory action. 6-Methylprednisolone,Medrol,Metipred,Urbason,6 Methylprednisolone
D011355 Prodrugs A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. Drug Precursor,Drug Precursors,Pro-Drug,Prodrug,Pro-Drugs,Precursor, Drug,Precursors, Drug,Pro Drug,Pro Drugs
D004355 Drug Stability The chemical and physical integrity of a pharmaceutical product. Drug Shelf Life,Drugs Shelf Lives,Shelf Life, Drugs,Drug Stabilities,Drugs Shelf Life,Drugs Shelf Live,Life, Drugs Shelf,Shelf Life, Drug,Shelf Live, Drugs,Shelf Lives, Drugs

Related Publications

H Okamoto, and K Mori, and K Ohtsuka, and H Ohuchi, and H Ishii
June 2006, Talanta,
H Okamoto, and K Mori, and K Ohtsuka, and H Ohuchi, and H Ishii
February 1988, Die Pharmazie,
H Okamoto, and K Mori, and K Ohtsuka, and H Ohuchi, and H Ishii
January 1988, Molekuliarnaia biologiia,
H Okamoto, and K Mori, and K Ohtsuka, and H Ohuchi, and H Ishii
February 1972, Journal of pharmaceutical sciences,
H Okamoto, and K Mori, and K Ohtsuka, and H Ohuchi, and H Ishii
January 1996, Physical review letters,
H Okamoto, and K Mori, and K Ohtsuka, and H Ohuchi, and H Ishii
June 2007, Biointerphases,
H Okamoto, and K Mori, and K Ohtsuka, and H Ohuchi, and H Ishii
March 2005, The journal of physical chemistry. B,
H Okamoto, and K Mori, and K Ohtsuka, and H Ohuchi, and H Ishii
June 2023, Chembiochem : a European journal of chemical biology,
H Okamoto, and K Mori, and K Ohtsuka, and H Ohuchi, and H Ishii
October 2019, Langmuir : the ACS journal of surfaces and colloids,
H Okamoto, and K Mori, and K Ohtsuka, and H Ohuchi, and H Ishii
December 2011, Langmuir : the ACS journal of surfaces and colloids,
Copied contents to your clipboard!